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BACKGROUND: Long-term cancer survivors in the United Kingdom are mostly followed up in a primary care setting by their general
practitioner; however, there is little research on the use of services. This study examines whether cancer survivors receive adequate
screening and preventative care in UK primary care.
PATIENTS AND METHODS: We identified a cohort of long-term survivors of breast, colorectal and prostate cancer with at least a 5-year
survival using the General Practice Research Database, with controls matched for age, gender and practice. We compared adherence
with cancer screening and the use of preventative care between cancer survivors and controls.
RESULTS: The cancer survivors’ cohort consisted of 18612 breast, 5764 colorectal and 4868 prostate cancer survivors. Most cancer
survivors receive cancer screening at the same levels as controls, except for breast cancer survivors who were less likely to receive a
mammogram than controls (OR¼0.78, 95% CI: 0.66–0.92). Long-term cancer survivors received comparable levels of influenza
vaccinations and cholesterol tests, but breast (OR 0.81, 95% CI: 0.74–0.87) and prostate cancer survivors (OR¼0.70, 95% CI: 0.57–
0.87) were less likely to receive a blood pressure test. All survivors were more likely to receive bone densitometry.
CONCLUSIONS: The provision and uptake of preventive care in a primary care setting in the United Kingdom is comparable between
the survivors of three common cancers and those who have not had cancer. However, long-term breast cancer survivors in this
cohort were less likely to receive a mammogram.
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There are increasing numbers of cancer survivors in the
United Kingdom. Current estimates indicate that there are
now more than 2 million people living past a diagnosis of cancer
in the United Kingdom, a number that is projected to increase
by 3% annually (Maddams et al, 2009). With increasing
numbers surviving many years after a diagnosis, it is important
to identify and control adverse sequelae of cancer and its
treatment, effectively manage comorbid conditions and
optimise the health of this population (Aziz, 2002; Aziz and
Rowland, 2003).
Cancer survivors are at increased risk of ill health because of a
number of factors, including second cancers, late effects related to
treatment and other comorbidities, including those unrelated
to cancer (Curtis et al, 1985; Orel et al, 1993; Sankila et al, 1995).
The risk of adverse health can be reduced through the use of
preventative services that can have an important part in ensuring
the long-term health of this population at risk (Carver et al, 2007).
However, cancer survivors have previously been shown to report
poorer health than the general population (Yabroff et al, 2004).
Previous research into the use of preventative care provided to
cancer survivors in the United States has provided mixed results.
Although the use of preventive services was better in some
cancer survivors, some breast cancer survivors had poorer uptake
of measures such as cholesterol screening and influenza
vaccination compared with non-cancer controls (Yeazel et al,
2004; Trask et al, 2005; Duffy et al, 2006; Snyder et al, 2009).
In contrast, others found that although breast cancer survivors
received adequate care, the uptake of preventative health in
long-term colorectal cancer survivors was worse than in those
without cancer (Earle et al, 2003; Earle and Neville, 2004). These
disparities in health care in the United States may result partly
from a focus on cancer follow-up at the expense of routine
preventative care for other diseases.
Despite the long-term risks in this population, there has
been very little research on the use of primary care services, and
specifically on the cancer screening and preventative health
behaviours, of cancer survivors in developed health economies
other than the United States (Khan et al, 2008). This paper aims to
fill this gap by examining the use of cancer and non-cancer-related
preventative health practices in a primary care-based cohort of
cancer survivors in the United Kingdom. In particular, we
examined whether screening is affected by a previous cancer
diagnosis, and whether cancer survivors receive similar preventa-
tive health care compared with individuals who have not had
cancer.
Received 17 December 2009; revised 12 February 2010; accepted 16
February 2010; published online 16 March 2010
*Correspondence: Dr NF Khan, Rosemary Rue Building, Old Road
Campus, University of Oxford, Oxford OX4 1PR, UK;
E-mail: nada.khan@dphpc.ox.ac.uk
British Journal of Cancer (2010) 102, 1085–1090

















The source of data
The General Practice Research Database (GPRD), which currently
contains information on 3.6 million representative patients from 450
primary care practices in the United Kingdom, was used to identify
the patients enrolled in this study (Walley and Mantgani, 1997). The
GPRD includes records on individual-level clinical diagnoses, test
results, prescriptions, referrals and all significant morbidity events
in the patient’s medical history (MHRA, 2004). The data undergo
quality control procedures, and several validation studies have
shown a high level of data completeness within the GPRD (Khan
et al, 2010). Screening and preventative care events were identified if
a medical or investigation code corresponding to the event was
present in the patient medical record. Clinical and investigation
code lists are available on request.
Definition of preventative services
We examined adherence to three national cancer screening
guidelines as outlined by the National Health Service (NHS)
cancer screening programme and the use of services for routine
screening of disease and disease prevention (Table 1). There are no
British guidelines on frequency of blood pressure testing, bone
density scanning or cholesterol tests; therefore, we examined the
receipt of one test every 3 years.
Description of participants
This study focuses on adult survivors of three cancer types: breast,
colorectal and prostate cancer. We defined cancer survivors (cases)
as those aged X30 years at the time of diagnosis, with at least a
5-year survival after diagnosis. Controls were patients with no
record of breast, colorectal or prostate cancer. For each case, up to
four controls were selected from the same primary care practice
and matched on the basis of age (within 1 year) and gender.
Inclusion and exclusion criteria for the use of screening
and preventative services
We only included patients who were within the age range and eligible
for cancer screening, or who did not have a history of previous
disease that would indicate the need for monitoring. We excluded
women with a history of hysterectomy in the analysis of cervical
smear, women with a history of bilateral mastectomy in the analysis
of mammography, prostate cancer survivors in the PSA test analysis
and breast cancer survivors o10 years after diagnosis in the use of
mammography. For preventative services, we excluded patients with
hypertension from blood pressure monitoring; patients with a clinical
history of diabetes, cerebrovascular disease/stroke, hypertension and
myocardial infarction from cholesterol testing; and patients with a
clinical history of osteoporosis from bone density scanning. These
patients will receive regular disease monitoring as directed by the
Quality and Outcomes Framework, an incentive programme for
payments to primary care practices from the English government
(Department of Health, 2006).
Statistical analyses
We compared the use of screening and preventative services
between cancer survivors and their matched controls over a 3-year
period between 1 September 2003 and 31 August 2006, which
represented the most recent data available in our data set. We
extended this analysis window to 5 years starting from 1
September 2001 for the analysis of cervical smear screening in
women aged 50–64 years to capture events corresponding to the
national cervical cancer screening programme guidelines (see
Table 1 for screening recommendations). Cancer survivors entered
the analysis along with their matched controls only when they
achieved a 5-year survival. In addition, cancer survivors and their
matched controls were censored from the analysis if the cancer
survivor died, was diagnosed with a second cancer or was
transferred out of the practice.
We first described the characteristics of the patients included in
each analysis and examined the percentage of cancer survivors and
controls receiving cancer screening and preventative services. To
determine the association between cancer survivor status and use
of preventative services compared with matched controls, we
used conditional logistic regression to calculate odds ratios
and 95% CIs, which accounts for the matching by comparing
cases with the controls for whom they were selected (Kirkwood
and Sterne, 2003). All analyses were carried out using Stata MP
statistical software, version 10.1 (StataCorp LP, College Station,
TX, USA).
Explanatory variables
We assigned each patient a Charlson comorbidity score on the
basis of their clinical history. The original Charlson score assigns
patients with cancer a weighted score of 2; however, we excluded
cancer as a comorbid disease when calculating individual Charlson
scores for both cancer survivors and their controls (Charlson et al,
1987). We included the number of consultations during the study
period as an explanatory variable for preventative care outcomes,
as patients who consult more frequently are more likely to have
incidental measurements, such as blood pressure. Information on
mastectomy was particularly important when considering receipt
of mammography. Therefore, we also linked the GPRD data set to
Table 1 Summary of UK guidance for cancer screening and preventative health services
National guidance Age range (years) Frequency of test
Screening test
Mammogram NHS Breast Cancer Screening Programme (2007–2008) 50–69 Once every 3 years
Cervical smear NHS Cervical Cancer Screening Programme (2007–2008) 25–49 Once every 3 years
50–64 Once every 5 years
PSA test Prostate Cancer Risk Management Programme (PCRMP)
(UK National Screening Committee, 2001)
50+ Patient request
Preventative health
Influenza vaccination National Institute for Health and Clinical Excellence (NICE) (2008c) 65+ Annually
Blood pressure test None — —
Bone density scan None — —
Cholesterol test (HDL, LDL,
serum cholesterol)
None — —
Abbreviations: HDL¼high-density lipoprotein; LDL¼low-density lipoprotein; PSA¼prostate-specific antigen.
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streatment data obtained from the English national cancer registry
network. A breast cancer patient was considered to have a history
of bilateral mastectomy if there was a clinical record for bilateral
mastectomy in GPRD records or cancer registration, or if there
were two clinical codes for mastectomy more than 1 year apart.
Not all mastectomy codes allowed us to distinguish between
unilateral and bilateral mastectomy; hence, we included a history
of mastectomy as a dichotomous covariate in the remainder of
women without a specific code for bilateral mastectomy. We
included a history of hormone therapy as identified through
prescription records in the GPRD as a covariate in the analysis for
bone density scanning. Body mass index was included in multi-
variate models that considered blood pressure, cholesterol testing
and bone density scanning. As patients nearing the end of their life
may be treated differently in primary care, we also included a
dichotomous variable indicating whether the patient died during
the analysis period, and tested for interactions between death and
receipt of screening and preventative care.
RESULTS
Patient characteristics and univariate analysis
The data set included 18612 breast cancer survivors, 5764
colorectal cancer survivors, 4868 prostate cancer survivors and
116418 controls (total n¼145662 patients). A summary of patient
characteristics is shown in Table 2. Colorectal and prostate cancer
survivors were quite elderly, and correspondingly a high propor-
tion had at least one comorbid disease.
Table 3 shows the prevalence of screening and preventative
service use among cancer survivors and controls. Rates of cervical
smear were much lower than expected, but similar in all cancer
survivors and controls, and a similar proportion of colorectal
cancer survivors and controls underwent mammography accord-
ing to the national guidelines. A lower proportion of breast cancer
survivors underwent a mammogram compared with controls.
In general, cancer survivors were more likely to receive bone
density scans, flu vaccination and cholesterol testing preventative
care than the control population. However, breast cancer survivors
were less likely to receive a blood pressure or cholesterol test
compared with controls. We examined these differences in
multivariate models.
Cancer screening
After adjusting for a history of mastectomy (n¼885), comorbid
disease and death, breast cancer survivors were 22% less likely to
receive a mammogram as indicated by the national screening
programme, compared with their matched controls (Table 4).
There was no difference in the receipt of mammography between
Table 2 Patient demographics
Breast Colorectal Prostate
Survivor Control Survivor Control Survivor Control
Numbers in analysis
Male — — 2912 11515 4868 19288
Female 18612 74284 2852 11331 — —
Age in years (s.d.) 67.65 (12.65) 75.13 (11.2) 76.86 (8.31)
Charlson score 40 8594 (46.2%) 31384 (42.3%) 3418 (59.3%) 12022 (52.6%) 3189 (65.5%) 11008 (57.1%)
Table 3 Univariate analysis, with numbers eligible for analysis
Breast Colorectal Prostate
Survivor Control Survivor Control Survivor Control
Screening exam
Mammogram 54.4% 59.5% 60.5% 58.5%
Number in analysis 2317 9974 513 2055 — —
Cervical smear
Aged 25–49 years 43.6% 40.1% 13.9% 15.2% — —
Number in analysis 755 3085 65 263
Aged 50–64 years 45.7% 44.4% 41.6% 41.9% — —
Number in analysis 3419 14061 178 855
PSA test — — 22.1% 19.0% — —
Number in analysis 2489 9859
Preventative health
Influenza vaccination 75.8% 74.4% 74.9% 73.2% 74.6% 70.2%
Number in analysis 9488 37803 4118 16325 3854 15275
Blood pressure 68.0% 69.2% 70.1% 70.4% 70.7% 68.7%
Number in analysis 9771 38815 2531 10668 2105 9252
Bone density scan 14.1% 10.3% 13.2% 10.5% 17.1% 9.3%
Number in analysis 14574 59471 4455 17954 3928 16026
Cholesterol test 31.9% 33.1% 37.8% 36.2% 39.9% 36.7%
Number in analysis 9072 35311 2306 9235 1720 7563
Abbreviation: PSA¼prostate-specific antigen.
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sfemale colorectal cancer survivors and matched controls. All breast
cancer survivors were more likely than controls to have a cervical
smear according to screening guidelines. There was no evidence
for a difference in the utilisation of cervical smear among
female colorectal cancer survivors compared with controls. As
some women receiving mammography or cervical smear may have
received screening just before or after the period of analysis, we
conducted a sensitivity analysis allowing for a 3-month interval
before and after the period of interest. The results were similar,
and are therefore not presented.
Colorectal cancer survivors over the age of 50 years were 19%
more likely to have a PSA test compared with controls. There was
no evidence for a difference in screening behaviours among cancer
survivors who died during the analysis period.
Preventative care
A summary of the multivariate models that consider preventative
care among cancer survivors and matched controls is presented in
Table 4 (full multivariate models are included in Appendix 1).
Each group of cancer survivors was more likely to receive bone
density scanning than their matched controls. In addition, cancer
survivors over the age of 65 years were more likely to receive an
influenza vaccination. In contrast, there were no differences in
cholesterol testing between cancer survivors and their matched
controls. Although colorectal cancer survivors were as likely to
receive a blood pressure test as their matched controls, both breast
and prostate cancer survivors were less likely to receive a
measurement of blood pressure over the analysis period. An
increasing number of primary care visits was the strongest
predictor of preventative care delivery.
DISCUSSION
This is the first paper reporting on the use of primary care services
in a large population of cancer survivors outside the United States.
In general, most cancer survivors in the United Kingdom receive
similar cancer screening and preventative health compared with
individuals who have not had cancer. All cancer survivors were
more likely to receive influenza vaccination and bone density
scans. However, in this cohort, long-term breast cancer survivors
were less likely to receive mammography, and breast and prostate
cancer survivors were less likely to receive a blood pressure test.
Second cancers can be detected at an earlier stage when
appropriate screening guidelines are met (Adami et al, 2001).
Colorectal cancer survivors in this cohort were more likely to
receive a PSA test, and breast cancer survivors were more likely to
receive a cervical smear than their matched controls. This finding
is understandable; individuals who have previously had cancer
may be motivated to identify second cancers at an early stage.
However, it is of concern that long-term breast cancer survivors in
this study are significantly less likely to receive breast cancer
screening than women without a history of breast cancer. Breast
cancer survivors are at risk of recurrence and primary cancer in
the contralateral breast; therefore, even women who have a
unilateral mastectomy should receive regular mammography
(Burstein and Winer, 2000). This is the not the first paper to
report the underuse of breast cancer screening; previous research
has shown the underuse of mammography in breast cancer
survivors and childhood cancer survivors despite an increased risk
of mortality (Andersen and Urban, 1998; Schapira et al, 2000;
Keating et al, 2006; Lash et al, 2007; Oeffinger et al, 2009).
Although lack of access to mammographic services contributes to
the underuse of breast screening amongst certain populations in
the United States, this is unlikely to explain cancer screening
practices in the United Kingdom, as all eligible women are invited
for free breast cancer screening through a national programme. It
is difficult to explore the reasons behind attendance at national
cancer screening programmes in a large, anonymised database
study. However, to increase screening rates, it is important to
understand why the use of mammography is lower in long-term
survivors.
The results from this analysis indicate that that in UK primary
care, cancer survivors generally receive similar preventative care
compared with matched controls, and indeed in some cases,
receive better care. It seems that the bone health of cancer
survivors is well managed in the United Kingdom; our analysis
shows that breast and prostate cancer survivors, who are at a
greater risk of osteoporosis after hormonal treatment, are
significantly more likely to receive a bone density scan than
matched controls (Chen et al, 2005). This is a large study with a
greater propensity for significant results, and although there are
deficiencies in the receipt of blood pressure testing among breast
and prostate survivors, the differences are small and may not be
clinically significant.
It is important to consider the results from this UK-based paper
and previous US-based studies in the context of differences in
national health-care delivery. In the United States, patients who
consulted their oncologist only in the long-term received poorer
preventative care for other diseases, but those who consulted both
primary and secondary care physicians received the best care
(Earle et al, 2003; Earle and Neville, 2004; Snyder et al, 2008, 2009).
Earle and colleagues suggested that a lack of clarity of the roles of
secondary and primary care in the United States may lead to
fragmentation of care, with cancer survivors unclear about whom
Table 4 Multivariate model for receipt of screening and preventative care (odds ratios from conditional logistic models)
Breast cancer Colorectal cancer Prostate cancer
Screening
a
Mammogram 0.78, 95% CI 0.66–0.92 1.11, 95% CI 0.77–1.61 —
Cervical smear —
Aged 25–49 years 1.37, 95% CI 1.11–1.68 0.66, 95% CI 0.21–2.15 —
Aged 50–64 years 1.14, 95% CI 1.03–1.25 1.13, 95% CI 0.72–1.75 —
PSA testing 1.19, 95% CI 1.06–1.34 —
Preventative care
Influenza vaccination
b 1.15, 95% CI 1.07–1.23 1.15, 95% CI 1.03–1.28 1.39, 95% CI 1.22–1.59
Blood pressure test
c 0.81, 95% CI 0.74–0.87 0.97, 95% CI 0.81–1.17 0.70, 95% CI 0.57–0.87
Bone density scan
c 1.26, 95% CI 1.10–1.44 1.23, 95% CI 1.05–1.43 1.59, 95% CI 1.23–2.06
Cholesterol testing
c 0.93, 95% CI 0.87–1.00 1.01, 95% CI 0.85–1.18 0.83, 95% CI 0.69–1.01
Abbreviations: BMI¼body mass index; CI¼confidence interval; PSA¼prostate-specific antigen. Cancer controls were used as the baseline comparison.
aAdjusted for Charlson
comorbidity score and death. Mammography analysis also adjusted for history of mastectomy.
bAdjusted for total number of consultations over analysis period, Charlson
comorbidity score and death.
cAdjusted for total number of consultations over analysis period, BMI, Charlson score and death. Bone density scan analysis also adjusted for
hormone treatment in breast and prostate cancer.
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sto consult for different aspects of their health care. Long-term
cancer survivors in the United Kingdom are unlikely to maintain
contact with oncologists, and will rely on their GP to provide care
for their cancer and other comorbidities after discharge from
hospital follow-up. Compared with the United States, the role of
primary care in the general health care of cancer survivors in the
United Kingdom is well defined, and this difference may explain
why cancer survivors in this cohort received preventative care at
similar levels to a non-cancer population. With the exception of
mammography for breast cancer survivors, there is certainly no
suggestion that cancer survivors are penalised by their status.
Several potential limitations of this study should be considered.
First, the data source was collected primarily for clinical use rather
than for research, and it is possible that some tests and diagnoses
were not fully recorded. However, because the analysis was
conducted as comparisons between cases and controls, complete-
ness of recording should not affect this analysis; it is unlikely that
the services considered in this paper would be coded preferentially
in either population. One proxy of the completeness of recording
in the GPRD is a comparison of rates of screening and preventative
care with national data. Rates of mammography through the
national screening programme are currently 73%, and hence may
be slightly underestimated in this GPRD cohort (2009). However,
rates of influenza captured in the GPRD closely mirror those of
national influenza vaccination, as estimated by the Department of
Health (NHS Immunization Information, 2005). This difference in
completeness of recording may reflect the fact that influenza
vaccination is likely to take place in primary care; however, breast
cancer screening occurs in specialised screening centres, and GPs
may record the event differently in the GPRD electronic patient
record. However, cervical screening, which does occur in UK
primary care, was not well captured in this GPRD cohort. National
coverage of cervical screening is B78%; therefore, the rates of
cervical smear are drastically underestimated in this study (2008).
This underestimate is a recognised problem in the GPRD because
of underrecording of cervical smear results in computerised
patient medical records before the widespread use of electronic
transfer of cervical smear results from laboratories.
Second, it has been suggested that research using administrative
data may underestimate rates of bilateral mastectomy (Nissen et al,
2008). However, the analysis in this paper was conducted using
surgery data from both cancer registries and primary care. Some of
the clinical codes used to identify mastectomy in the GPRD were
not precise enough to determine whether the procedure was
bilateral or unilateral. This may be a limitation, as patients
receiving a bilateral mastectomy will not be eligible for breast
screening. However, to account for this, we excluded any women
with a specific primary care code for bilateral mastectomy, or two
mastectomy codes more than a year apart. This definition of
bilateral mastectomy resulted in an overall rate of 4.2% in the
cohort of breast cancer survivors, which corresponds to rates in
the SEER (Surveillance, Epidemiology and End Results) database
(Tuttle et al, 2007). We also conducted a sensitivity analysis
excluding all women with any clinical code for mastectomy. The
results were similar and therefore not presented.
Finally, because we are using a primary care database, we are
unlikely to account for preventative care or screening occurring in
hospital or in specialised clinics. However, in the United Kingdom,
the majority of cancer survivors are discharged to the care of their
GP 3 to 5 years after diagnosis. Therefore, the majority of their care
will occur in primary care and is likely to be coded in the GPRD.
As cancer survivors are living longer, the current challenge in
primary care is to maximise the quality and duration of life after
cancer. This can be achieved through screening, preventative
services and advice to patients, which can reduce the risk of second
cancers and other potential comorbidities. There are now guide-
lines for risk-based surveillance among childhood cancer survi-
vors; management of bone loss among breast cancer survivors; and
identification of cardiac and pulmonary late-effects in long-term
survivors; however, more work is required in this area to direct
GPs who will be responsible for the long-term health care of this
population (Carver et al, 2007; Reid et al, 2008; Hudson et al,
2009). There is a need for evidence-based guidelines to direct case
finding and preventative care in primary care for elderly cancer
survivors, who require care of general health and comorbid
disease, as well as potential late effects of cancer and its treatment.
A further understanding of the factors that contribute to late
effects and the appropriate risk-based surveillance will help
towards maintaining the good health of this population.
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